## Stanley S Stylli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4074037/publications.pdf

Version: 2024-02-01

172207 168136 3,069 78 29 53 citations g-index h-index papers 82 82 82 4649 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression. International Journal of Molecular Sciences, 2022, 23, 2770.	1.8	21
2	Identification and isolation of slow-cycling glioma stem cells. Methods in Cell Biology, 2022, , 21-30.	0.5	2
3	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. Uro, 2022, 2, 74-92.	0.3	3
4	Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for the rapeutic intervention. , $2021, , 319-334$ .		0
5	Temporal patterns of visual recovery following pituitary tumor resection: A prospective cohort study. Journal of Clinical Neuroscience, 2021, 86, 252-259.	0.8	9
6	IL-10 in glioma. British Journal of Cancer, 2021, 125, 1466-1476.	2.9	26
7	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 1811-1820.	2.0	11
8	The renin-angiotensin system in central nervous system tumors and degenerative diseases. Frontiers in Bioscience, 2021, 26, 628.	0.8	4
9	Novel Treatment Strategies for Glioblastoma—A Summary. Cancers, 2021, 13, 5868.	1.7	5
10	Extracellular vesicles and their role in glioblastoma. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 227-252.	2.7	30
11	Novel Treatment Strategies for Glioblastoma. Cancers, 2020, 12, 2883.	1.7	42
12	Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs. Cancers, 2020, 12, 2888.	1.7	9
13	Serum microRNA is a biomarker for post-operative monitoring in glioma. Journal of Neuro-Oncology, 2020, 149, 391-400.	1.4	27
14	Prognostic Utility of Optical Coherence Tomography for Long-Term Visual Recovery Following Pituitary Tumor Surgery. American Journal of Ophthalmology, 2020, 218, 247-254.	1.7	21
15	Association between elevated cerebrospinal fluid D-dimer levels and delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage. Journal of Clinical Neuroscience, 2020, 76, 177-182.	0.8	5
16	Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System. Cells, 2019, 8, 1364.	1.8	27
17	<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p> . OncoTargets and Therapy, 2019, Volume 12, 635-645.	1.0	124
18	Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer. Cellular Signalling, 2019, 57, 2-9.	1.7	10

#	Article	IF	CITATIONS
19	Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance. Advances in Experimental Medicine and Biology, 2019, 1139, 1-21.	0.8	14
20	Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma. Cancer Investigation, 2019, 37, 144-155.	0.6	17
21	Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Experimental Cell Research, 2019, 374, 353-364.	1.2	31
22	Circulating tumor stem cells and glioblastoma: A review. Journal of Clinical Neuroscience, 2019, 61, 5-9.	0.8	24
23	Tumour stem cells in schwannoma: A review. Journal of Clinical Neuroscience, 2019, 62, 21-26.	0.8	13
24	Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 2019, 130, 1446-1452.	0.9	13
25	Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide. Journal of Neurosurgery, 2018, 129, 598-610.	0.9	18
26	Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers, 2018, 10, 526.	1.7	15
27	Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs. Translational Oncology, 2018, 11, 1406-1418.	1.7	15
28	Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures. Experimental and Molecular Pathology, 2018, 105, 23-31.	0.9	21
29	The role of interleukinâ€'6â€'STAT3 signalling in glioblastoma (Review). Oncology Letters, 2018, 16, 4095-4104.	0.8	61
30	A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker. PLoS ONE, 2018, 13, e0189452.	1.1	39
31	miRNA expression profiling of cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 2017, 126, 1131-1139.	0.9	55
32	STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology, 2017, 451, 15-23.	1.6	49
33	The emergent role of exosomes in glioma. Journal of Clinical Neuroscience, 2017, 35, 13-23.	0.8	115
34	Cancer exosomes in cerebrospinal fluid. Translational Cancer Research, 2017, 6, S1352-S1370.	0.4	10
35	Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. Medical Oncology, 2016, 33, 53.	1.2	21
36	A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: Increasing glutamate uptake with PPARÎ <sup>3</sup> agonists. Journal of Clinical Neuroscience, 2015, 22, 21-28.	0.8	10

#	Article	IF	Citations
37	Repair mechanisms help glioblastoma resist treatment. Journal of Clinical Neuroscience, 2015, 22, 14-20.	0.8	48
38	Optical coherence tomography predicts visual outcome for pituitary tumors. Journal of Clinical Neuroscience, 2015, 22, 1098-1104.	0.8	121
39	Using bioluminescence imaging in glioma research. Journal of Clinical Neuroscience, 2015, 22, 779-784.	0.8	16
40	Mouse models of glioma. Journal of Clinical Neuroscience, 2015, 22, 619-626.	0.8	64
41	MicroRNA as potential biomarkers in Glioblastoma. Journal of Neuro-Oncology, 2015, 125, 237-248.	1.4	47
42	The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells. Oncotarget, 2015, 6, 21301-21314.	0.8	27
43	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biology and Therapy, 2014, 15, 623-632.	1.5	27
44	Visual acuity and pattern of visual field loss at presentation in pituitary adenoma. Journal of Clinical Neuroscience, 2014, 21, 735-740.	0.8	79
45	Expression of the adaptor protein Tks5 in human cancer: Prognostic potential. Oncology Reports, 2014, 32, 989-1002.	1.2	22
46	The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy. Current Drug Targets, 2014, 15, 1341-1353.	1.0	65
47	Glycogen synthase kinase- $3\hat{l}^2$ (GSK- $3\hat{l}^2$ ) and its dysregulation in glioblastoma multiforme. Journal of Clinical Neuroscience, 2013, 20, 1185-1192.	0.8	36
48	The role of Stat3 in glioblastoma multiforme. Journal of Clinical Neuroscience, 2013, 20, 907-911.	0.8	104
49	Prognostic significance of Tks5 expression in gliomas. Journal of Clinical Neuroscience, 2012, 19, 436-442.	0.8	47
50	Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation. Journal of Cell Science, 2009, 122, 2727-2740.	1.2	135
51	Invadopodia: At the cutting edge of tumour invasion. Journal of Clinical Neuroscience, 2008, 15, 725-737.	0.8	190
52	Two-photon characterization and microscopy of porphyrin photosensitisers., 2007,,.		0
53	Two-photon absorption cross-sections and time-resolved fluorescence imaging using porphyrin photosensitisers. Photochemical and Photobiological Sciences, 2007, 6, 1019-1026.	1.6	27
54	Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination. Biochemical and Biophysical Research Communications, 2006, 351, 1018-1023.	1.0	7

#	Article	IF	CITATIONS
55	Photodynamic therapy of cerebral glioma $\hat{a} \in A$ review Part II $\hat{a} \in C$ Clinical studies. Journal of Clinical Neuroscience, 2006, 13, 709-717.	0.8	86
56	Photodynamic therapy of cerebral glioma $\hat{a} \in A$ review Part I $\hat{a} \in A$ biological basis. Journal of Clinical Neuroscience, 2006, 13, 615-625.	0.8	55
57	Dipyridophenazine Complexes of Cobalt(III): DNA Photocleavage and Photobiology. Australian Journal of Chemistry, 2005, 58, 206.	0.5	13
58	Photodynamic therapy of high grade glioma – long term survival. Journal of Clinical Neuroscience, 2005, 12, 389-398.	0.8	199
59	Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. Journal of Clinical Neuroscience, 2004, 11, 584-596.	0.8	81
60	The biocompatibility of BioGlue with the cerebral cortex: a pilot study. Journal of Clinical Neuroscience, 2004, 11, 631-635.	0.8	23
61	Overexpression of Hyaluronan Synthase-2 Reduces the Tumorigenic Potential of Glioma Cells Lacking Hyaluronidase Activity. Neurosurgery, 2002, 50, 1311-1318.	0.6	72
62	Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [ 18 F]fluoromisonidazole (FMISO). Nuclear Medicine and Biology, 2002, 29, 191-197.	0.3	42
63	Synovial ablation in a rabbit rheumatoid arthritis model using photodynamic therapy. ANZ Journal of Surgery, 2002, 72, 517-522.	0.3	22
64	Phase I and Pharmacokinetic Study of Photodynamic Therapy for High-Grade Gliomas Using a Novel Boronated Porphyrin. Journal of Clinical Oncology, 2001, 19, 519-524.	0.8	93
65	Induction of CD44 expression in stab wounds of the brain: long term persistence of CD44 expression. Journal of Clinical Neuroscience, 2000, 7, 137-140.	0.8	19
66	Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. Cancer Chemotherapy and Pharmacology, 1998, 41, 423-426.	1.1	1
67	Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. Cancer Chemotherapy and Pharmacology, 1997, 40, 202-208.	1.1	1
68	Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma. British Journal of Cancer, 1996, 73, 514-521.	2.9	13
69	Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 12126-12130.	3.3	67
70	Aluminium phthalocyanine mediated photodynamic therapy in experimental malignant glioma. Journal of Clinical Neuroscience, 1995, 2, 146-151.	0.8	15
71	Phthalocyanine photosensitizers for the treatment of brain tumours. Journal of Clinical Neuroscience, 1995, 2, 64-72.	0.8	8
72	Evaluation of a morpholinothiolporphyrin for use in photodynamic therapy. British Journal of Cancer, 1994, 70, 398-400.	2.9	6

#	Article	IF	Citations
73	Antitumour effect of MX2, a new morpholino anthracycline against C6 glioma cells and its cytotoxic effect in combination with photodynamic therapy. Journal of Clinical Neuroscience, 1994, 1, 47-52.	0.8	7
74	Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1785-1789.	3.3	134
75	Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy. British Journal of Cancer, 1992, 65, 321-328.	2.9	50
76	PHOTODYNAMIC THERAPY IN THE TREATMENT OF SUBCUTANEOUSLY IMPLANTED HUMAN BLADDER TUMOUR. ANZ Journal of Surgery, 1992, 62, 643-649.	0.3	2
77	Selective Uptake of Hematoporphyrin Derivative into Human Cerebral Glioma. Neurosurgery, 1990, 26, 248-254.	0.6	78
78	Peripheral biomarkers in glioblastoma patientsâ€"is it all just HOTAIR?. Non-coding RNA Investigation, 0, 2, 32-32.	0.6	2